Nippon Chemiphar Co. Ltd. has disclosed morphinan derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of cough, pain, pruritus, substance abuse and dependence, and liver, respiratory, neurological and cardiovascular disorders.